Get started
Author

Jonathan E. Grim

Notch Activation Induces Endothelial Cell Cycle Arrest and Participates in Contact Inhibition: Role of p21 Cip1 Repression
2004 · Michela Noseda, Linda Chang, et al. · Molecular and Cellular Biology · 218
Isoform- and cell cycle–dependent substrate degradation by the Fbw7 ubiquitin ligase
2008 · Jonathan E. Grim, Michael P. Gustafson, et al. · The Journal of Cell Biology · 116
PDF
Fbw7 and p53 Cooperatively Suppress Advanced and Chromosomally Unstable Intestinal Cancer
2012 · Jonathan E. Grim, Sue E. Knoblaugh, et al. · Molecular and Cellular Biology · 97
Fbw7 dimerization determines the specificity and robustness of substrate degradation
2013 · Markus Welcker, Elizabeth A. Larimore, et al. · Genes & Development · 93
PDF
Pan-cancer transcriptional signatures predictive of oncogenic mutations reveal that Fbw7 regulates cancer cell oxidative metabolism
2018 · Ryan J. Davis, Mehmet Gönen, et al. · Proceedings of the National Academy of Sciences · 43
Zanidatamab + chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA).
2023 · Elena Elimova, Jaffer A. Ajani, et al. · Journal of Clinical Oncology · 35
A Nucleolar Isoform of the Fbw7 Ubiquitin Ligase Regulates c-Myc and Cell Size
2005 · Markus Welcker, Amir Orian, et al. · Current Biology · 23
PDF
Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer
2026 · Kohei Shitara, Elena Elimova, et al. · New England Journal of Medicine · 22
Targeted therapy in gastroesophageal cancers: past, present and future: Figure 1.
2015 · Janghee Woo, Stacey A. Cohen, et al. · Gastroenterology report · 20
PDF
Fbxw7 hotspot mutations and human colon cancer: mechanistic insights from new mouse models
2013 · Jonathan E Grim · Gut · 16
Zanidatamab + chemotherapy (CT) ± tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced, unresectable, or metastatic gastroesophageal adenocarcinoma (mGEA): Primary analysis from HERIZON-GEA-01.
2026 · Elena Elimova, Sun Young Rha, et al. · Journal of Clinical Oncology · 13
Cycling without CDK2?
2003 · Jonathan E Grim, Bruce E Clurman · Trends in Cell Biology · 12
Insertional mutagenesis using the Sleeping Beauty transposon system identifies drivers of erythroleukemia in mice
2019 · Keith R. Loeb, Bridget T. Hughes, et al. · Scientific Reports · 9
PDF
Regulation of cell proliferation in a stratified culture system of epithelial cells from prostate tissue
2006 · Michael P. Gustafson, Chang Xu, et al. · Cell and Tissue Research · 7
Zanidatamab + chemotherapy (CT) ± tislelizumab for first-line (1L) HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (mGEA): PD-L1 subgroup analysis from HERIZON-GEA-01.
2026 · Sun Young Rha, Kohei Shitara, et al. · Journal of Clinical Oncology · 3
A (heat) shocking development: FBXW 7 loss unleashes HSF 1 to drive melanoma invasion and metastasis
2015 · Eunpi Cho, Jonathan E. Grim · Pigment Cell & Melanoma Research · 2
PDF
Mantle cell lymphoma relapsed after autologous stem cell transplantation: a single-center experience
2020 · Aaron Wu, Solomon A. Graf, et al. · Blood Research · 1
PDF
Notch Regulation by the Fbw7/hcdc4/Sel-10 Ubiquitin Ligase.
2006 · Jonathan E. Grim, Olga Sala, et al. · Blood · 1
Characterization and management of gastrointestinal (GI) adverse events (AEs) with zanidatamab + chemotherapy (CT) ± tislelizumab in first-line (1L) HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (mGEA): Analysis from HERIZON-GEA-01.
2026 · Elena Elimova, Sun Young Rha, et al. · Journal of Clinical Oncology
Abstract 1340: A mouse model of metastatic intestinal cancers associated with Fbw7- and p53-loss
2012 · Jonathan E. Grim, Sue Knoblaugh, et al. · Cancer Research
Works count: 20
Citation count: 728
H-index: 12
I10-index: 12
Year
Topic
Type